Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Broad-spectrum antibiotics target multiple gram-positive and gram-negative bacteria, and can collaterally damage the gut microbiota. Yet, our knowledge of the extent of damage, the antibiotic activity spectra, and the resistance mechanisms of gut microbes is sparse. This limits our ability to mitigate microbiome-facilitated spread of antibiotic resistance. In addition to antibiotics, non-antibiotic drugs affect the human microbiome, as shown by metagenomics as well as in vitro studies. Microbiome-drug interactions are bidirectional, as microbes can also modulate drugs. Chemical modifications of antibiotics mostly function as antimicrobial resistance mechanisms, while metabolism of non-antibiotics can also change the drugs' pharmacodynamic, pharmacokinetic, and toxic properties. Recent studies have started to unravel the extensive capacity of gut microbes to metabolize drugs, the mechanisms, and the relevance of such events for drug treatment. These findings raise the question whether and to which degree these reciprocal drug-microbiome interactions will differ across individuals, and how to take them into account in drug discovery and precision medicine. This review describes recent developments in the field and discusses future study areas that will benefit from systems biology approaches to better understand the mechanistic role of the human gut microbiota in drug actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 1×
“…overcome this limitation through differentiation of stem cells into specific intestinal cell types, such as enterocytes and goblet cells, forming crypt macrostructures, and encompass intestinal properties, such as barrier functions (Sato et al , 2009; Yin et al , 2014; Pearce et al , 2018).”
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“…of how the gut microbiome impacts anticancer immunotherapy by PD-1 (Tanoue et al , 2019), CTLA-4 blockage (V (cid:2) etizou et al , 2015; Sivan et al , 2015; Mager et al , 2020) or in cyclophosphamide therapy (Viaud et al , 2013), all resulting in findings of high transferability to…”
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life
Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H., Zhong, H., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.004 · Cited by 3,315
Environment dominates over host genetics in shaping human gut microbiota
Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., Costea, P. I., Godneva, A., Kalka, I. N., Bar, N., et al. (2018) · Nature · doi:10.1038/nature25973 · Cited by 2,859 · cited 1×
“This composition is established in early stages of life (B € ackhed et al , 2015; Wampach et al , 2017) and is dependent more on the environment than on host genetics (Rothschild et al , 2018).”
Population-level analysis of gut microbiome variation
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M. J., Valles-Colomer, M., Vandeputte, D., et al. (2016) · Science · doi:10.1126/science.aad3503 · Cited by 2,400 · cited 3×
“…disease, and how it changes over time, life stages, different geographic regions, and in response to environmental factors has increased dramatically over the last decade (The Integrative HMP (iHMP) Research Network Consortium, 2019; Pasolli et al , 2019; Nayfach et al , 2019; Falony et al , 2016).”
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Extensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905 · cited 2×
“Comparable to the described systematic bottom-up approach to test drug activity on representative panels of bacteria in isolation (Maier et al , 2018), similar efforts have been employed to deduce their metabolic activity against a large panel of drugs (Zimmermann et al , 2019b).”
Self-citationCox, L. M., Yamanishi, S., Sohn, J., Alekseyenko, A. V., Leung, J. M., Cho, I., Kim, S. G., Li, H., Gao, Z., Mahana, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.052 · Cited by 1,859 · cited 2×
“A number have examined the short-and long-term effects of antibiotics ( e.g ., Cox et al , 2014; Cho et al , 2012; Nobel et al , 2015; Ruiz et al , 2017).”
Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., Kotler, E., Zur, M., Regev-Lehavi, D., Brik, R. B.-Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.041 · Cited by 1,695 · cited 1×
“…moment are based on generic processes with limited success and/or adverse outcomes, such as fecal transplantation or administration of probiotics (Zmora et al , 2018; Suez et al , 2018; DeFilipp et al , 2019) For host-targeted drugs, increasing evidence suggests that they are associated with…”
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Antibiotics in early life alter the murine colonic microbiome and adiposity
Cho, I., Yamanishi, S., Cox, L., Methé, B. A., Zavadil, J., Li, K., Gao, Z., Mahana, D., Raju, K., Teitler, I., et al. (2012) · Nature · doi:10.1038/nature11400 · Cited by 1,613 · cited 2×
“A number have examined the short-and long-term effects of antibiotics ( e.g ., Cox et al , 2014; Cho et al , 2012; Nobel et al , 2015; Ruiz et al , 2017).”
Pasolli, E., Asnicar, F., Manara, S., Zolfo, M., Karcher, N., Armanini, F., Beghini, F., Manghi, P., Tett, A., Ghensi, P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.001 · Cited by 1,591
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407 · cited 1×
“…gut microbiome impacts anticancer immunotherapy by PD-1 (Tanoue et al , 2019), CTLA-4 blockage (V (cid:2) etizou et al , 2015; Sivan et al , 2015; Mager et al , 2020) or in cyclophosphamide therapy (Viaud et al , 2013), all resulting in findings of high transferability to humans (reviewed in…”
The pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398 · cited 1×
“Probiotics describe specific bacterial strains intended for therapeutic purposes (Suez et al , 2019 ).”
The Integrative Human Microbiome Project
The Integrative HMP (iHMP) Research Network Consortium, Proctor, L. M., Creasy, H. H., Fettweis, J. M., Lloyd-Price, J., Mahurkar, A., Zhou, W., Buck, G. A., Snyder, M. P., Strauss, J. F., et al. (2019) · Nature · doi:10.1038/s41586-019-1238-8 · Cited by 1,381
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · cited 1×
“For example, proton-pump inhibitors (PPI)s are among the drugs with the most pronounced effect on the gut microbiome composition (Imhann et al , 2016).”
How informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334 · cited 1×
“In contrast to invertebrate models, rodent models have been the standard for pharmaceutical and microbiome research for decades (Nguyen et al , 2015).”
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281 · cited 1×
“…with limited success and/or adverse outcomes, such as fecal transplantation or administration of probiotics (Zmora et al , 2018; Suez et al , 2018; DeFilipp et al , 2019) For host-targeted drugs, increasing evidence suggests that they are associated with shifts in gut microbiome composition.”
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., Gurjao, C., Manders, F., Dalmasso, G., Stege, P. B., et al. (2020) · Nature · doi:10.1038/s41586-020-2080-8 · Cited by 1,208 · cited 2×
“…or secreted molecules, such as lipopolysaccharides and muramyl-dipeptides (Nigro et al , 2014; Naito et al , 2017), and of microbiome-derived small molecules, such as short-chain fatty acids and indolacrylic acid (Park et al , 2016; Wlodarska et al , 2017; Pleguezuelos-Manzano et al , 2020).”
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
Self-citationA defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145 · cited 2×
“Rodent models have further contributed to our understanding of how the gut microbiome impacts anticancer immunotherapy by PD-1 (Tanoue et al , 2019), CTLA-4 blockage (V (cid:2) etizou et al , 2015; Sivan et al , 2015; Mager et al , 2020) or in cyclophosphamide therapy (Viaud et al , 2013), all resulting in findings of…”
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011 · cited 1×
“This leads to an accumulation of glycoursodeoxycholic acid, which inhibits the intestinal farnesoid X receptor (FXT) signaling and thereby improves various metabolic outcomes in mice, including hyperglycemia (Sun et al , 2018).”
Next-generation probiotics: the spectrum from probiotics to live biotherapeutics
O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.57 · Cited by 971 · cited 1×
“…genetically modified to express specific therapeutic properties ( e.g ., therapeutic proteins (Gurbatri et al , 2020 )), whereas next-generation probiotics are based on microbial isolates from the gut microbiota that are re-inserted, possibly after in vitro modification (O ’ Toole et al , 2017 ).”
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967 · cited 1×
“Remarkably, several model systems such as Caenorhabditis elegans (Cabreiro et al , 2013), mice (Shin et al , 2014), and rats (Bauer et al , 2018) were instrumental in elucidating these metformin – microbiome – host interactions, highlighting the translation of these phenomena between evolutionarily…”
Recovery of gut microbiota of healthy adults following antibiotic exposure
Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0257-9 · Cited by 875 · cited 1×
“Initial data indicate that the microbiota of healthy patients can partially rebound post-antibiotic treatment (Rashid et al , 2015; Palleja et al , 2018).”
Self-citationTrends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · cited 1×
“Membrane-bound G-protein-coupled receptors (GPCR) are a prime target for pharmacological interventions, currently representing more than one-third of the targets for prescribed drugs (Rask-Andersen et al , 2011).”
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811 · cited 1×
“Stool samples provide a non-invasive starting point for studying the complex, self-assembled human microbiome (Bolan et al , 2016 ) and can be incubated with drugs ex vivo (Maurice et al , 2013 ; van de Steeg et al , 2018 ).”
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14177-z · Cited by 791 · cited 3×
“However, the functional implications of these taxonomic shifts, for example in terms of altered metabolic capacities and/or antibiotic resistance repertoires, need to be assessed separately for each compound (Vich Vila et al , 2020).”
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753 · cited 4×
“This experimental setup has the advantage that microbial community members do not have to be selected a priori and encompasses microbial interactions that can impact drug metabolism, as shown for sequential L-dopa metabolism by two different species (Maini Rekdal et al , 2019).”
InfluentialShifting the balance: antibiotic effects on host–microbiota mutualism
Willing, B. P., Russell, S. L., & Finlay, B. B. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2536 · Cited by 747 · cited 1×
“Hence strong perturbations, such as dietary shifts and antibiotic consumption, can unbalance micro-biome stability, with so far unpredictable recovery (Willing et al , 2011; Falony et al , 2016; Lynn et al , 2018).”
New insights from uncultivated genomes of the global human gut microbiome
Nayfach, S., Shi, Z. J., Seshadri, R., Pollard, K. S., & Kyrpides, N. C. (2019) · Nature · doi:10.1038/s41586-019-1058-x · Cited by 737 · cited 2×
“…disease, and how it changes over time, life stages, different geographic regions, and in response to environmental factors has increased dramatically over the last decade (The Integrative HMP (iHMP) Research Network Consortium, 2019; Pasolli et al , 2019; Nayfach et al , 2019; Falony et al , 2016).”
Fröhlich, E. E., Farzi, A., Mayerhofer, R., Reichmann, F., Jačan, A., Wagner, B., Zinser, E., Bordag, N., Magnes, C., Fröhlich, E., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.02.020 · Cited by 720
Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013) · Science · doi:10.1126/science.1235872 · Cited by 704 · cited 4×
“…differences in the communities’ drug-metabolizing capacity (Zimmermann et al , 2019b) (Fig 2), which are corroborated by differences in the drug-metabolizing potential for different bacterial species and strains (Lindenbaum et al , 1981; Haiser et al , 2013; Zimmermann et al , 2019b).”
InfluentialGut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656 · cited 1×
“Testing microbial communities or single bacterial strains, up to 65% of the assayed drugs were metabolized, suggesting that the microbial drug metabolism is a far more common phenomenon than the few anecdotal examples collected over the last few decades (reviewed in Wilson & Nicholson, 2017).”
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647 · cited 1×
“Further, probiotic bacteria can be genetically modified to express specific therapeutic properties ( e.g ., therapeutic proteins (Gurbatri et al , 2020 )), whereas next-generation probiotics are based on microbial isolates from the gut microbiota that are re-inserted, possibly after in vitro…”
Jackson, M. A., Verdi, S., Maxan, M.-E., Shin, C. M., Zierer, J., Bowyer, R. C. E., Martin, T., Williams, F. M. K., Menni, C., Bell, J. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05184-7 · Cited by 616
Walter, J., Armet, A. M., Finlay, B. B., & Shanahan, F. (2020) · Cell · doi:10.1016/j.cell.2019.12.025 · Cited by 596 · cited 1×
“This approach provides a powerful tool to investigate signaling along the drug – microbiome – host axis with many conceivable ways for improvement ( e.g ., enrichment and purification steps, defined microbial consortia, ex vivo incubation of drugs and microbes) (Walter et al , 2020).”
Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans
Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M. S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.010 · Cited by 572
Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506 · cited 1×
“Recently, so-called “ stoolbanks ” became more sophisticated in order to promote accessibility to fecal microbiota transplantation in clinical practice (Cammarota et al , 2019 ).”
Commensal bacteria make GPCR ligands that mimic human signalling molecules
Cohen, L. J., Esterhazy, D., Kim, S.-H., Lemetre, C., Aguilar, R. R., Gordon, E. A., Pickard, A. J., Cross, J. R., Emiliano, A. B., Han, S. M., et al. (2017) · Nature · doi:10.1038/nature23874 · Cited by 500 · cited 1×
“Several studies have recently been published employing high-throughput GPCR activation assays to screen for micro-biome-produced GPCR ligands (Cohen et al , 2017; Colosimo et al , 2019; Chen et al , 2019).”
Zheng, D.-W., Dong, X., Pan, P., Chen, K.-W., Fan, J.-X., Cheng, S.-X., & Zhang, X.-Z. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0423-2 · Cited by 495 · cited 1×
“In preclinical models of colorectal cancer, phages of the tumor-associated Fusobacterium nucleatum have even been used for targeted drug delivery (Zheng et al , 2019 ).”
THE ROLE OF INTESTINAL BACTERIA IN THE METABOLISM OF SALICYLAZOSULFAPYRIDINE
PEPPERCORN, M. A., & GOLDMAN, P. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29238-2 · Cited by 450
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423 · cited 1×
“…differences in the communities’ drug-metabolizing capacity (Zimmermann et al , 2019b) (Fig 2), which are corroborated by differences in the drug-metabolizing potential for different bacterial species and strains (Lindenbaum et al , 1981; Haiser et al , 2013; Zimmermann et al , 2019b).”
Li, L., Ning, Z., Zhang, X., Mayne, J., Cheng, K., Stintzi, A., & Figeys, D. (2020) · Microbiome · doi:10.1186/s40168-020-00806-z · Cited by 328 · cited 1×
“To investigate such responses systematically, robust high-throughput ways are needed to grow communities (Box 1) and to follow species abundance, ideally at an absolute quantification level ( e.g ., by metaproteomics (Li et al , 2020), Fig 2).”
Nutritional preferences of human gut bacteria reveal their metabolic idiosyncrasies
Tramontano, M., Andrejev, S., Pruteanu, M., Klünemann, M., Kuhn, M., Galardini, M., Jouhten, P., Zelezniak, A., Zeller, G., Bork, P., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0123-9 · Cited by 295
Self-citationAn atlas of β-glucuronidases in the human intestinal microbiome
Pollet, R. M., D'Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., Pellock, S. J., Patterson, L. M., Creekmore, B. C., Isenberg, H. N., et al. (2017) · Structure · doi:10.1016/j.str.2017.05.003 · Cited by 289
Nigro, G., Rossi, R., Commere, P.-H., Jay, P., & Sansonetti, P. J. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.05.003 · Cited by 277
Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy
Pryor, R., Norvaisas, P., Marinos, G., Best, L., Thingholm, L. B., Quintaneiro, L. M., De Haes, W., Esser, D., Waschina, S., Lujan, C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.003 · Cited by 274
Stability of the human faecal microbiome in a cohort of adult men
Mehta, R. S., Abu-Ali, G. S., Drew, D. A., Lloyd-Price, J., Subramanian, A., Lochhead, P., Joshi, A. D., Ivey, K. L., Khalili, H., Brown, G. T., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-017-0096-0 · Cited by 273 · cited 1×
“Further, healthy individuals retain a largely stable microbiota composition for most of their adulthood (Som-mer et al , 2017; Mehta et al , 2018).”
Bauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications
Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., Batard, E., Knights, D., & Montassier, E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14451 · Cited by 263
Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
Gil-Cruz, C., Perez-Shibayama, C., De Martin, A., Ronchi, F., van der Borght, K., Niederer, R., Onder, L., Lütge, M., Novkovic, M., Nindl, V., et al. (2019) · Science · doi:10.1126/science.aav3487 · Cited by 260 · cited 1×
“Microbial communities can interact with and affect the host with peptides/proteins (Gil-Cruz et al , 2019), RNA (Liu et al , 2016), and metabolites (Uchimura et al , 2018; Koh & B € ackhed, 2020).”
Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans
Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P. T., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.040 · Cited by 254 · cited 1×
“…elegant studies, the C. elegans model allowed to identify bacterial nucleotide metabolism genes that affect chemotherapeutic efficacy on the host (Scott et al , 2017; Garc (cid:2) ıa-Gonz (cid:2) alez et al , 2017) or to understand how diet can affect metformin’s positive effect on lifespan by…”
Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics
García-González, A. P., Ritter, A. D., Shrestha, S., Andersen, E. C., Yilmaz, L. S., & Walhout, A. J. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.046 · Cited by 243
Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients
Ticinesi, A., Milani, C., Lauretani, F., Nouvenne, A., Mancabelli, L., Lugli, G. A., Turroni, F., Duranti, S., Mangifesta, M., Viappiani, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10734-y · Cited by 211
IS p-AMINOBENZENESULPHONAMIDE THE ACTIVE AGENT IN PRONTOSIL THERAPY ?
Fuller, A. T. (1937) · The Lancet · doi:10.1016/s0140-6736(00)97447-6 · Cited by 162
Uchimura, Y., Fuhrer, T., Li, H., Lawson, M. A., Zimmermann, M., Yilmaz, B., Zindel, J., Ronchi, F., Sorribas, M., Hapfelmeier, S., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.004 · Cited by 153 · cited 1×
“Microbial communities can interact with and affect the host with peptides/proteins (Gil-Cruz et al , 2019), RNA (Liu et al , 2016), and metabolites (Uchimura et al , 2018; Koh & B € ackhed, 2020).”
Self-citationSelwyn, F. P., Cheng, S. L., Klaassen, C. D., & Cui, J. Y. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067504 · Cited by 138
Nakayama, H., Kinouchi, T., Kataoka, K., Akimoto, S., Matsuda, Y., & Ohnishi, Y. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00005 · Cited by 120 · cited 1×
“…enzymes, leading to drug activation ( e.g ., sulfasalazine, Sousa et al , 2014), inactivation ( e.g ., L-dopa and digoxin (Linden-baum et al , 1981; Haiser et al , 2013; Maini Rekdal et al , 2019)) or toxicity ( e.g ., sorivudine and brivudine, (Zimmermann et al , 2019a; Nakayama et al , 1997).”
Cited by
Unravelling the collateral damage of antibiotics on gut bacteria
Maier, L., Goemans, C. V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., Garcia-Santamarina, S., Cacace, E., Zhang, B., et al. (2021) · Nature · doi:10.1038/s41586-021-03986-2 · Cited by 391
Self-citationThe evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective
Valles-Colomer, M., Menni, C., Berry, S. E., Valdes, A. M., Spector, T. D., & Segata, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02260-4 · Cited by 114
Targeting the human gut microbiome with small-molecule inhibitors
Woo, A. Y. M., Aguilar Ramos, M. A., Narayan, R., Richards-Corke, K. C., Wang, M. L., Sandoval-Espinola, W. J., & Balskus, E. P. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00471-4 · Cited by 42
Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder
Trujillo-Del Río, C., Tortajada-Pérez, J., Gómez-Escribano, A. P., Casterá, F., Peiró, C., Millán, J. M., Herrero, M. J., & Vázquez-Manrique, R. P. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111670 · Cited by 19
Metadata
- Authors
- Zimmermann, M., Patil, K. R., Typas, A., & Maier, L.
- Venue
- Molecular Systems Biology
- Published
- 2021-03
- Volume
- 17
- Issue
- 3
- Pages
- e10116-e10116
- ISSN
- 1744-4292 (ISSN-L)
- OpenAlex
- W3138837064
- Cited by
- 121
- References
- 64
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.